Strategies for Endogenous Spinal Cord Repair: HPMA Hydrogel to Recruit Migrating Endogenous Stem Cells

Author(s):  
Araceli Espinosa-Jeffrey ◽  
Karlos Oregel ◽  
Laurent Wiggins ◽  
Remelyn Valera ◽  
Kathrin Bosnoyan ◽  
...  
Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3214
Author(s):  
Krisztián Pajer ◽  
Tamás Bellák ◽  
Antal Nógrádi

Hundreds of thousands of people suffer spinal cord injuries each year. The experimental application of stem cells following spinal cord injury has opened a new era to promote neuroprotection and neuroregeneration of damaged tissue. Currently, there is great interest in the intravenous administration of the secretome produced by mesenchymal stem cells in acute or subacute spinal cord injuries. However, it is important to highlight that undifferentiated neural stem cells and induced pluripotent stem cells are able to adapt to the damaged environment and produce the so-called lesion-induced secretome. This review article focuses on current research related to the secretome and the lesion-induced secretome and their roles in modulating spinal cord injury symptoms and functional recovery, emphasizing different compositions of the lesion-induced secretome in various models of spinal cord injury.


2002 ◽  
Author(s):  
Tanja Zigova ◽  
Evan Y. Snyder ◽  
Paul R. Sanberg

2012 ◽  
Vol 349 (1) ◽  
pp. 349-362 ◽  
Author(s):  
Beatrice Sandner ◽  
Peter Prang ◽  
Francisco J. Rivera ◽  
Ludwig Aigner ◽  
Armin Blesch ◽  
...  

2012 ◽  
Vol 366 (20) ◽  
pp. 1940-1942 ◽  
Author(s):  
Evan Y. Snyder ◽  
Yang D. Teng

2004 ◽  
Vol 180 (12) ◽  
pp. 637-639 ◽  
Author(s):  
Jeffrey V Rosenfeld ◽  
Grant R Gillett

2015 ◽  
Vol 16 (1) ◽  
pp. 3-8
Author(s):  
Marina Gazdic ◽  
Vladislav Volarevic ◽  
Miodrag Stojkovic

ABSTRACTStem cell therapy offers several attractive strategies for spinal cord repair. The regenerative potential of pluripotent stem cells was confirmed in an animal model of Spinal Cord Injury (SCI); nevertheless, optimized growth and differentiation protocols along with reliable safety assays should be established prior to the clinical application of hESCs and iPSCs. Th e therapeutic effects of mesenchymal stem cells (MSCs) in SCI result from neurotrophin secretion, angiogenesis, and antiinflammatory actions. Several preclinical SCI studies have reported that the occurrence of axonal extension, remyelination and neuroprotection occur after the transplantation of olfactory ensheathing cells (OECs). The transplantation of neural stem cells NSCs (NSCs) promotes partial functional improvement after SCI because of their potential to differentiate into neurons, oligodendrocytes, and astrocytes. The ideal source of stem cells for safe and efficient cell-based therapy for SCI remains a challenging issue that requires further investigation.


Sign in / Sign up

Export Citation Format

Share Document